Flipkart plans food delivery pilot to challenge Swiggy, Zomato

Fractal Analytics IPO Allotment Today: How to check status on NSE, BSE, MUFG Intime; listing details

Lenskart hits fresh high as Q3 PAT rises sharply; brokerages raise targets

Jupiter Wagons shares fall over 4% after Q3 profit slips 35%

Why are HUL shares falling despite 2.2x jump in Q3 FY26 PAT? Explained

Chief Economic Advisor-led panel formed for regulatory impact assessment: SEBI Chairman

IT Stocks Mayhem! Infosys, TCS, Wipro shares slide on AI fears — Buy the dip or wait? Anil Singhvi explains

Zero tariff access expected to significantly boost India’s agriculture exports to the US: SBI report

M&M shares fall despite 33% rise in Q3 profit; should you buy the dip?

HUL Q3 FY26 Results: PAT jumps 121% to Rs 6,603 crore on ice cream demerger boost; Revenue up 6%

Should you buy, sell or hold Dr Reddy's Labs shares? Here's what brokerages suggest

Zee Business Research Team expects steady revenue growth and moderate profit gains, with US pricing pressure and Revlimid erosion weighing on overall performance.

Dr Reddy’s Q2 Results Preview: Muted quarter likely; Revlimid drag may offset India gains

The Hyderabad-based drug major Dr Reddy's Laboratories had reported a profit of Rs 1,379 crore for the October-December period of last fiscal.

Dr Reddy's Q3 FY25 Results: Drug major's profit up 2% at Rs 1,413 crore

Dr Reddy's Laboratories on Thursday said Kazakhstan revenue authority has levied a penalty of Rs 28.7 lakh on its subsidiary.

Dr Reddy's unit gets penalty of Rs 28.7 lakh from Kazakhstan authority

The fine was imposed due to an error in the date of the invoice and also in the name of the reference standard versus import license.

Dr Reddy's Labs gets Rs 27 lakh penalty from Mexican drug regulator

The drug regulatory body of Mexico has imposed a penalty of MXN 6,51,420 (Rs 28 Lakh) on the company for deviation from prescribed guidelines for filing intimation of import of a reference standard for one of the active pharmaceutical ingredient

Dr Reddy's fined Rs 28 lakh by Mexican drug regulator

Earlier, the USFDA had issued a Form 483 with two observations to the two units following inspection which was conducted from May 8 to May 17, 2024.

Dr Reddy's Laboratories share price: Company gets establishment inspection report from USFDA for Visakhapatnam units

Stock of the Day: What is Anil Singhvi's opinion on Dr Reddy's Laboratories? See in this video.

Stock of the Day: What is Anil Singhvi's opinion on Dr Reddy's Laboratories?

Dr Reddy's Labs share price:&nbsp;Dr Reddy's Laboratories reported a 36 per cent increase in its consolidated profit after tax at Rs 1,307 crore for the quarter that ended March 2024, aided by robust sales in the US market.&nbsp;

Dr Reddy's Labs Q4 results miss estimates, stock slips nearly 5%; Should you buy, sell or hold?

As of 11:04 a.m., shares of Dr Reddy's Laboratories traded 1.65 per cent or Rs 99.5 higher, at Rs 6,147.1 apiece on BSE. The market capitalisation of the company at around the same time stood at Rs 1,02,379.92 crore.

Dr Reddy's Labs enters into distribution partnership with Sanofi India; stock rises 

BreakingNews | Complaint in US court against Dr Reddy's subsidiary, complaint in case related to generic Revlimid drug Allegation of monopoly of generic Revlimid drug.

Breaking News | Complaint in US court against Dr Reddy's subsidiary

After closing at Rs 6152.45 on Friday evening, the stock of Dr. Reddy's Laboratories&nbsp;started its journey on Monday at Rs 6200.05. It jumped to its all-time high minutes after starting the trading session on Monday.

Dr Reddy's Labs hits an all-time high after US FDA issues EIR to its Hyderabad facility

The company's consolidated profit after tax (PAT) jumped by 11 per cent, while its revenue from operations was up by seven per cent Year-on-Year (YoY).

&nbsp;

Dr Reddy's Laboratories zooms to an all-time time after reporting above-estimate December quarter results

At around 12:42&nbsp;p.m., shares of Dr Reddy's Laboratories&nbsp;traded 0.85&nbsp;per cent or Rs 46.8&nbsp;lower at Rs 5,483.1&nbsp;apiece. The stock fell for the second straight day and the market capitalisation of the company stood at Rs 91,737.16 crore.

Dr Reddy's Labs Hyderabad facility gets 9 observations from US drug regulator; shares fall

Dr Reddy Q4 results 2023 preview:&nbsp;The pharmaceutical company is likely to report a 13 per cent year-on-year (YoY) increase in its consolidated revenue to Rs 6,174 crore against Rs 5,475 crore logged in Q4FY2023, according to Zee Business Research.&nbsp;

Dr Reddy's Q4 2023 preview: Here is what to expect from the drug maker

Top Gainers &amp; Losers:&nbsp;TCS will kick start the Q4 earnings season later in the day. Industrial Production data for February and March inflation rates are scheduled to be announced post-market hours.

Top Gainers & Losers: Dr Reddy’s Labs, Bajaj Auto end in green, Power Grid dips nearly 2%

The National Pharmaceutical Pricing Authority (NPPA) on Monday fixed the prices under the Drugs (Price Control) Order 2013 based on the decision of the 109th authority meeting held on February 21 this year, according to a PTI report.

Pharma stocks a mixed bag as drug regulator NPPA fixes retail price of 74 drug formulations

Brokerages are bullish on Dr Reddy's Laboratories, Bajaj Auto, and skeptical on Wipro. Here's what top brokerages recommend on some of the key stocks in focus today.

Wipro, Bajaj Auto, Dr Reddy's among stocks in focus today | Check What Brokerage firm Recommends

The acquisition will complement Dr Reddy's US retail prescription pharmaceutical business with limited competition products.

Dr Reddy's to buy US generic product portfolio of Australia-based Mayne Pharma

<h2>Shares of Tata Motors and Bajaj Auto were trading flat with a positive bias at Rs 422.40 and Rs 3,693 per share on the NSE in the early morning session on Wednesday.</h2>

Tata Motors, Bajaj Auto, Dr Reddy’s Laboratories, and Cipla are in focus ahead of Q3 results today

dr-reddys-laboratories-0

Zee Business Research Team expects steady revenue growth and moderate profit gains, with US pricing pressure and Revlimid erosion weighing on overall performance.

The Hyderabad-based drug major Dr Reddy's Laboratories had reported a profit of Rs 1,379 crore for the October-December period of last fiscal.

Dr Reddy's Laboratories on Thursday said Kazakhstan revenue authority has levied a penalty of Rs 28.7 lakh on its subsidiary.

The fine was imposed due to an error in the date of the invoice and also in the name of the reference standard versus import license.

Zee Business

Home

Personal Finance

India

Economy

Tech

Auto

Markets

Jobs

Indian Railways

World

Videos

Photos

Dr Reddy's Laboratories News- Zee Business provides latest news on Dr Reddy's Laboratories, Dr Reddy's Laboratories news Today, Top News on Dr Reddy's Laboratories, update on Dr Reddy's Laboratories Stay updated with business news, breaking news headlines.

Dr Reddy's Laboratories Latest News- Top News on Dr Reddy's Laboratories, Update on Dr Reddy's Laboratories, Dr Reddy's Laboratories News Today, Breaking News Headlines, Business News | Zee Business

Dr Reddy's Laboratories

Should you buy, sell or hold Dr Reddy's Labs shares? Here's what brokerages suggest

Dr Reddy’s Q2 Results Preview: Muted quarter likely; Revlimid drag may offset India gains

Dr Reddy's Q3 FY25 Results: Drug major's profit up 2% at Rs 1,413 crore

Dr Reddy's unit gets penalty of Rs 28.7 lakh from Kazakhstan authority

Dr Reddy's Labs gets Rs 27 lakh penalty from Mexican drug regulator

Dr Reddy's fined Rs 28 lakh by Mexican drug regulator

RECOMMENDED

Flipkart plans food delivery pilot to challenge Swiggy, Zomato

Fractal Analytics IPO Allotment Today: How to check status on NSE, BSE, MUFG Intime; listing details

Lenskart hits fresh high as Q3 PAT rises sharply; brokerages raise targets

Jupiter Wagons shares fall over 4% after Q3 profit slips 35%

Why are HUL shares falling despite 2.2x jump in Q3 FY26 PAT? Explained

Chief Economic Advisor-led panel formed for regulatory impact assessment: SEBI Chairman

IT Stocks Mayhem! Infosys, TCS, Wipro shares slide on AI fears — Buy the dip or wait? Anil Singhvi explains

Zero tariff access expected to significantly boost India’s agriculture exports to the US: SBI report

M&M shares fall despite 33% rise in Q3 profit; should you buy the dip?

HUL Q3 FY26 Results: PAT jumps 121% to Rs 6,603 crore on ice cream demerger boost; Revenue up 6%

Dr Reddy's Laboratories share price: Company gets establishment inspection report from USFDA for Visakhapatnam units

Stock of the Day: What is Anil Singhvi's opinion on Dr Reddy's Laboratories?

Dr Reddy's Labs Q4 results miss estimates, stock slips nearly 5%; Should you buy, sell or hold?

Dr Reddy's Labs enters into distribution partnership with Sanofi India; stock rises

Breaking News | Complaint in US court against Dr Reddy's subsidiary

Dr Reddy's Labs hits an all-time high after US FDA issues EIR to its Hyderabad facility

Dr Reddy's Laboratories zooms to an all-time time after reporting above-estimate December quarter results

Dr Reddy's Labs Hyderabad facility gets 9 observations from US drug regulator; shares fall

Dr Reddy's Q4 2023 preview: Here is what to expect from the drug maker

Top Gainers & Losers: Dr Reddy’s Labs, Bajaj Auto end in green, Power Grid dips nearly 2%

Pharma stocks a mixed bag as drug regulator NPPA fixes retail price of 74 drug formulations

Wipro, Bajaj Auto, Dr Reddy's among stocks in focus today | Check What Brokerage firm Recommends

Dr Reddy's to buy US generic product portfolio of Australia-based Mayne Pharma

Tata Motors, Bajaj Auto, Dr Reddy’s Laboratories, and Cipla are in focus ahead of Q3 results today

Top News

Flipkart plans food delivery pilot to challenge Swiggy, Zomato

Fractal Analytics IPO Allotment Today: How to check status on NSE, BSE, MUFG Intime; listing details

Lenskart hits fresh high as Q3 PAT rises sharply; brokerages raise targets

Jupiter Wagons shares fall over 4% after Q3 profit slips 35%

Why are HUL shares falling despite 2.2x jump in Q3 FY26 PAT? Explained

Chief Economic Advisor-led panel formed for regulatory impact assessment: SEBI Chairman